Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2734 | Otilimab Wiki | 1.00 |
| drug3738 | Standard of care Wiki | 0.20 |
| drug2916 | Placebo Wiki | 0.04 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The purpose of this study is to assess the efficacy of PF-06650833 in addition to standard-of-care compared to standard-of-care treatment alone in improving outcomes in patients with COVID-19.
Description: All-cause mortality at Day 29 (end of planned treatment period).
Measure: All-cause mortality at Day 29 Time: Up to 29 daysDescription: Proportion of patients alive, extubated, and receiving no more than low flow oxygen supplementation by nasal cannula or face mask (excluding extubation for compassionate purposes in terminal patients). This would correspond to an at least 2 point decrease in the NIAID ordinal scale. The NIAID scale is as follows: Not hospitalized, no limitations on activities Not hospitalized, limitations on activities and/or requiring home oxygen Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise) Hospitalized, requiring supplemental oxygen Hospitalized, on non-invasive ventilation or high-flow oxygen devices Hospitalized, on invasive mechanical ventilation or ECMO Death
Measure: Disease Severity (8 point scale) Time: 29 daysDescription: Proportion of patients alive, extubated, and receiving no more than low flow oxygen supplementation by nasal cannula or face mask (excluding extubation for compassionate purposes in terminal patients). This would correspond to an at least 2 point decrease in the NIAID ordinal scale (1 = not hospitalized, no limitations on activities, and 8 = death) at Day 61.
Measure: Disease Severity (8 point scale) Time: 61 daysDescription: Proportion of patients alive, extubated, and receiving any level oxygen supplementation, including non-invasive positive pressure ventilation or high flow oxygen device (excluding extubation for compassionate purposes in terminal patients). This would correspond to an at least 1-point decrease in the NIAID ordinal scale (1 = not hospitalized, no limitations on activities, and 8 = death) at Day 29.
Measure: Disease Severity (8 point scale) Time: 29 daysDescription: Proportion of patients alive, extubated, and receiving any level oxygen supplementation, including non-invasive positive pressure ventilation or high flow oxygen device (excluding extubation for compassionate purposes in terminal patients). This would correspond to an at least 1-point decrease in the NIAID ordinal scale (1 = not hospitalized, no limitations on activities, and 8 = death) at Day 61.
Measure: Disease Severity (8 point scale) Time: 61 daysDescription: Percentage of patients in each category of the NIAID 8-point ordinal scale of disease severity at Day 8. The ordinal scale is an assessment of the clinical status at the first assessment of a given study day in which 1 = not hospitalized, no limitations on activities, and 8 = death.
Measure: Disease Severity (8 point scale) Time: 8 daysDescription: Percentage of patients in each category of the NIAID 8-point ordinal scale of disease severity at Day 15. The ordinal scale is an assessment of the clinical status at the first assessment of a given study day in which 1 = not hospitalized, no limitations on activities, and 8 = death.
Measure: Disease Severity (8 point scale) Time: 15 daysDescription: Percentage of patients in each category of the NIAID 8-point ordinal scale of disease severity at Day 22. The ordinal scale is an assessment of the clinical status at the first assessment of a given study day in which 1 = not hospitalized, no limitations on activities, and 8 = death.
Measure: Disease Severity (8 point scale) Time: 22 daysDescription: Percentage of patients in each category of the NIAID 8-point ordinal scale of disease severity at Day 29. The ordinal scale is an assessment of the clinical status at the first assessment of a given study day in which 1 = not hospitalized, no limitations on activities, and 8 = death.
Measure: Disease Severity (8 point scale) Time: 29 daysDescription: Percentage of patients in each category of the NIAID 8-point ordinal scale of disease severity at Day 61. The ordinal scale is an assessment of the clinical status at the first assessment of a given study day in which 1 = not hospitalized, no limitations on activities, and 8 = death.
Measure: Disease Severity (8 point scale) Time: 61 daysDescription: Mortality rate at day 61
Measure: Mortality Time: 61 daysDescription: Time to a 1-point decrease in the NIAID 8-point ordinal scale of disease severity (1 = not hospitalized, no limitations on activities, and 8 = death).
Measure: Disease Severity (8 point scale) Time: 29 daysDescription: Time to a 2-point decrease in the NIAID 8-point ordinal scale of disease severity.
Measure: Disease Severity (8 point scale) Time: 29 daysDescription: Change from baseline in the ordinal scale from Day 1 to Days 3.
Measure: Disease Severity (8 point scale) Time: 3 daysDescription: Change from baseline in the ordinal scale from Day 1 to Days 5.
Measure: Disease Severity (8 point scale) Time: 5 daysDescription: Change from baseline in the ordinal scale from Day 1 to Days 8.
Measure: Disease Severity (8 point scale) Time: 8 daysDescription: Change from baseline in the ordinal scale from Day 1 to Days 11.
Measure: Disease Severity (8 point scale) Time: 11 daysDescription: Change from baseline in the ordinal scale from Day 1 to Days 15.
Measure: Disease Severity (8 point scale) Time: 15 daysDescription: Change from baseline in the ordinal scale from Day 1 to Days 22.
Measure: Disease Severity (8 point scale) Time: 22 daysDescription: Change from baseline in the ordinal scale from Day 1 to Days 29.
Measure: Disease Severity (8 point scale) Time: 29 daysDescription: PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)
Measure: P/F ratio Time: Up to 29 daysDescription: The SOFA evaluates 6 variables, each representing an organ system (one for the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems), and scored from 0 (normal) to 4 (high degree of dysfunction/failure). Thus, the maximum score may range from 0 to 24.
Measure: Change of the SOFA score. Time: Up to 29 daysDescription: The duration is days spent on mechanical ventilation.
Measure: Duration (days) of mechanical ventilation Time: Up to 29 daysDescription: The number of days hospitalized not on a ventilator.
Measure: Ventilator free days. Time: Up to 29 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports